The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
This drug class confers benefits in diabetic patients with heart failure, CV disease, and renal disease, but it is also associated with major adverse events.
According to the CDC’s Behavioral Risk Factor Surveillance System 2013, nearly 71% of adults with atherosclerotic cardiovascular disease use aspirin regularly.